Scarica l'app Stockscreener
46.08
0.43%
-0.20
Dopo l'orario di chiusura:
46.08
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MIRM Giù?
Forum
Previsione
Precedente Chiudi:
$46.28
Aprire:
$46.8
Volume 24 ore:
534.24K
Relative Volume:
1.08
Capitalizzazione di mercato:
$2.26B
Reddito:
$307.03M
Utile/perdita netta:
$-99.81M
Rapporto P/E:
-22.27
EPS:
-2.0695
Flusso di cassa netto:
$-27.20M
1 W Prestazione:
-3.74%
1M Prestazione:
-1.91%
6M Prestazione:
+18.61%
1 anno Prestazione:
+83.44%
Intervallo 1D:
$45.61
$47.17
Intervallo di 1 settimana:
$45.61
$48.49
Portata 52W:
$23.14
$54.23
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
Nome
Mirum Pharmaceuticals Inc
Settore
Industria
Telefono
650-667-4085
Indirizzo
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
Confronta MIRM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MIRM
Mirum Pharmaceuticals Inc
|
46.08 | 2.26B | 307.03M | -99.81M | -27.20M | -2.0695 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.55 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
635.83 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
593.47 | 36.20B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.02 | 35.08B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
262.60 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-04-17 | Iniziato | Stifel | Buy |
| 2023-12-18 | Reiterato | H.C. Wainwright | Buy |
| 2023-11-20 | Ripresa | JP Morgan | Overweight |
| 2023-11-13 | Iniziato | Morgan Stanley | Overweight |
| 2023-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-10-17 | Ripresa | Evercore ISI | Outperform |
| 2023-09-20 | Iniziato | JMP Securities | Mkt Outperform |
| 2022-09-01 | Iniziato | Citigroup | Buy |
| 2021-09-20 | Iniziato | JP Morgan | Overweight |
| 2020-08-07 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2020-08-03 | Iniziato | H.C. Wainwright | Buy |
| 2020-07-31 | Iniziato | Piper Sandler | Overweight |
| 2020-06-25 | Iniziato | Robert W. Baird | Outperform |
| 2019-08-12 | Iniziato | Citigroup | Buy |
| 2019-08-12 | Iniziato | Evercore ISI | Outperform |
| 2019-08-12 | Iniziato | Guggenheim | Buy |
| 2019-08-12 | Iniziato | ROTH Capital | Buy |
| 2019-08-12 | Iniziato | Raymond James | Outperform |
Mostra tutto
Mirum Pharmaceuticals Inc Borsa (MIRM) Ultime notizie
Mirum Pharmaceuticals Says Livmarli Approved in Japan for Pruritus - Marketscreener.com
LIVMARLI Now Approved In Japan For ALGS And PFIC - Marketscreener.com
First-Ever Treatment for ALGS and PFIC Approved in Japan: LIVMARLI Makes History - StockTitan
Mirum Pharmaceuticals: Set Fair For Share Price MomentumReversing My Sell Call (MIRM) - Seeking Alpha
Maintaining An 'Accumulate' Rating On Mirum Pharmaceuticals, Lots To Like (NASDAQ:MIRM) - Seeking Alpha
Exploring 3 High Growth Tech Stocks in the US Market - Simply Wall St
(MIRM) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Mirum's Heavy Dependence on Livmarli for Revenues Remains a Woe - Nasdaq
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Looks Inexpensive But Perhaps Not Attractive Enough - Simply Wall St
Mirum Pharmaceuticals SVP Jolanda Howe sells $107,342 in stock By Investing.com - Investing.com Australia
Mirum’s Rare Disease Strategy: A Blueprint For Sustainable Growth - News & Insights
Mirum Pharmaceuticals SVP Jolanda Howe sells $107,342 in stock - Investing.com
Mirum Pharmaceuticals CEO sells $1.2 million in stock By Investing.com - Investing.com South Africa
Mirum Pharmaceuticals president sells $348k in stock - Investing.com India
Mirum Pharmaceuticals CEO sells $1.2 million in stock - Investing.com
Mirum Pharmaceuticals’ SVP Jolanda Howe sells $2.4 million in stock By Investing.com - Investing.com UK
Mirum Pharmaceuticals director Heron buys $24,214 in stock By Investing.com - Investing.com Australia
Mirum Pharmaceuticals director Heron buys $24,214 in stock - Investing.com India
Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI® (maralixibat) Oral Solution for the Treatment of PFIC in Patients Three Months of Age and Older - Business Wire
Mirum Pharmaceuticals’ SWOT analysis: FDA nod boosts rare disease stock - Investing.com India
Mirum Pharmaceuticals director Heron buys $99,517 in stock - Investing.com India
Mirum Pharmaceuticals director Heron buys $99,517 in stock By Investing.com - Investing.com Australia
Mirum Pharmaceuticals’ SWOT analysis: FDA nod boosts rare disease stock By Investing.com - Investing.com South Africa
Mirum Pharmaceuticals at Leerink Conference: Growth in Rare Diseases By Investing.com - Investing.com Canada
(MIRM) Proactive Strategies - Stock Traders Daily
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - WICZ
Mirum Pharmaceuticals Strengthens Growth Strategy with Strategic New Hires and Equity Incentives - StockTitan
Mirum Pharmaceuticals director Heron buys $83,661 in stock By Investing.com - Investing.com South Africa
Mirum Pharmaceuticals director Heron buys $83,661 in stock - Investing.com India
MIRMMirum Pharmaceuticals Latest Stock News & Market Updates - StockTitan
Director’s Bold Move: Major Stock Purchase in Mirum Pharmaceuticals! - TipRanks
Mirum Pharmaceuticals’ president sells $676,928 in stock - Investing.com India
Mirum Pharmaceuticals’ president sells $676,928 in stock By Investing.com - Investing.com UK
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Bought by Rhumbline Advisers - Defense World
Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target Raised to $72.00 - Defense World
Wall Street Analysts Predict a 26.18% Upside in Mirum Pharmaceuticals (MIRM): Here's What You Should Know - MSN
Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target Raised to $72.00 at HC Wainwright - MarketBeat
Analyst Estimates: Here's What Brokers Think Of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) After Its Full-Year Report - Yahoo Finance UK
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates - MSN
(MIRM) Technical Data - Stock Traders Daily
Mirum Pharmaceuticals: Strong Buy Rating Driven by Promising Financial Growth and Clinical Advancements - TipRanks
Mirum Pharmaceuticals (NASDAQ:MIRM) Trading Down 8.2% After Earnings Miss - MarketBeat
Robert W. Baird Issues Positive Forecast for Mirum Pharmaceuticals (NASDAQ:MIRM) Stock Price - MarketBeat
H.C. Wainwright lifts Mirum stock target to $72, maintains Buy By Investing.com - Investing.com UK
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q4 2024 Earnings Call Transcript - Insider Monkey
Mirum Pharmaceuticals’ Earnings Call Highlights Growth and Future Prospects - TipRanks
Mirum Pharmaceuticals (NASDAQ:MIRM) Announces Quarterly Earnings Results - MarketBeat
MIRM's Q4 Loss Wider Than Expected, Revenues Beat Estimates - MSN
Mirum Pharmaceuticals Inc Azioni (MIRM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.46%
0.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):